Core Viewpoint - PMGC Holdings Inc. has announced an update on its capital structure, emphasizing its strong financial position and commitment to strategic priorities through its subsidiaries [1][2]. Capital Structure and Financial Position - As of February 25, 2025, PMGC's capital structure includes 4,042,295 common shares outstanding, 4,931 stock options with a weighted-average exercise price of 4.91 per share [5]. - The company has zero debt, indicating a strong balance sheet [5]. - Recent capital raises include 1.9 million from a warrant inducement offering in January 2025 [5]. Subsidiaries and Business Focus - PMGC Holdings operates through three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [3]. - Northstrive Biosciences focuses on developing aesthetic medicines, particularly targeting obesity treatment with its lead asset, EL-22 [5]. - PMGC Research is dedicated to R&D, leveraging Canadian research grants and partnerships with universities to commercialize technologies [5]. - PMGC Capital is a multi-strategy investment firm that seeks undervalued companies and assets to drive sustainable growth [5].
PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market